RESUMO
OBJECTIVE: In 2009, a new strain of influenza A, H1N1, was detected in two children in the United States. It spread quickly and became pandemic (pH1N1), disproportionately affecting children. The aim of the present study was to describe our experience with pH1N1 in a large pediatric hospital. METHODS: We reviewed the clinical records of all of the children diagnosed as having influenza A at Children's Hospital, New Orleans, LA, for the period April 2009 to May 2010. Diagnosis was made by rapid influenza test or direct fluorescent antibody. Specimens form hospitalized children were sent to the Louisiana Office of Public Health for confirmation by reverse-transcription-polymerase chain reaction. RESULTS: During the 14-month study period, 10,470 children were tested and 1463 (14%) tested positive for influenza A. Boys were more commonly infected than girls (53% vs 47%, P < .001). Of the cases, 1308 (89%) were ambulatory and 155 (11%) were hospitalized. Hospitalized children were younger, more frequently white, had non-Medicaid insurance, and had comorbidity. Of the 155 admissions, 14 (9%) were admitted to the intensive care unit. Having a comorbidity increased and being black decreased the chances of being admitted to the intensive care unit. Three children died, all with severe neurologic or respiratory predisposing illness. Eight cases of hospital-onset influenza and 6 of repeat infection were detected. CONCLUSIONS: pH1N1 burdened pediatric facilities during the 2009-2010 influenza season. Even though most cases were mild and self-limited, some resulted in severe disease and long-term complications.
Assuntos
Vírus da Influenza A Subtipo H1N1 , Influenza Humana/epidemiologia , Pandemias , Assistência Ambulatorial , Criança , Feminino , Hospitalização , Hospitais Pediátricos , Humanos , Influenza Humana/diagnóstico , Influenza Humana/mortalidade , Tempo de Internação , Louisiana/epidemiologia , Masculino , RecidivaRESUMO
An outbreak of influenza A pandemic (H1N1) 2009 occurred among campers and staff at a summer camp attended by children with hematologic and oncologic conditions. The overall attack rate was 36% and was highest among children and adolescents (43%), persons with cancer (48%), and persons with sickle cell disease (82%).
Assuntos
Acampamento , Surtos de Doenças , Doenças Hematológicas/complicações , Vírus da Influenza A Subtipo H1N1 , Influenza Humana/epidemiologia , Neoplasias/complicações , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Estâncias para Tratamento de Saúde , Humanos , Influenza Humana/diagnóstico , Influenza Humana/virologia , Pessoa de Meia-Idade , Pandemias , Adulto JovemRESUMO
BACKGROUND: The 2017-2018 influenza season was of high severity. Circulating influenza strains change periodically, making it important to determine vaccine effectiveness on an annual basis, especially for susceptible populations. The primary aim of our study was to estimate the effectiveness of the influenza vaccine among children. Secondary aims were to assess the effect of previous season vaccination and intraseasonal waning of immunity. METHODS: Children 6 months to 17 years of age tested for influenza during the 2017-2018 season were included. Clinical charts were reviewed, and immunization status was confirmed via the Louisiana Immunization Registry. Influenza vaccine effectiveness (IVE) was estimated in a test-negative design by comparing vaccination status of influenza-positive vs influenza-negative cases. RESULTS: A total of 3595 children were included, 26% of whom tested positive for influenza, mostly type A (79%); 15% had received an influenza vaccine prior to illness: 8% among the influenza-positive and 17% among influenza-negative cases (P <.0001). IVE for the 2017-2018 influenza season was 52% overall (95% confidence interval, 38%-62%), 49% for influenza A, and 60% for influenza B. While receiving current year (2017-2018) vaccine had the most effect, receiving the previous year (2016-2017) vaccine had a small benefit and no interference. We found no evidence of waning immunity of the vaccine for the 2017-2018 season. CONCLUSIONS: IVE was moderate for children. Previous year vaccination had a small but significant benefit and there was no evidence of waning immunity in our cohort. Ongoing national and local surveillance is important to understand the benefit of influenza vaccination.
Assuntos
Vacinas contra Influenza/imunologia , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Estados Unidos/epidemiologiaRESUMO
A 21-question survey was conducted among parents attending 4 pediatric outpatient practices to assess their knowledge, perceptions, and attitudes about fever. One hundred and ninety-seven surveys were included. Most commonly the participating parent was the mother. Parents used mainly axillary thermometers to measure child's temperature and mentioned integers for their definition of fever, 100°F being the most frequent answer. Most parents would treat all fevers and would use alternating antipyretics. Parents had a generally negative perception of fever: only one third thought fever may have some benefit, and more than half thought there must be some risk. A positive perception of fever was associated with parental educational level but not with information by the pediatrician. There is much confusion about fever among our parents, a negative perception is prevalent, and parents seem to receive-or recall-little information from the pediatrician.
Assuntos
Antipiréticos/administração & dosagem , Febre/diagnóstico , Febre/tratamento farmacológico , Conhecimentos, Atitudes e Prática em Saúde , Pais/educação , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Louisiana , Masculino , Inquéritos e Questionários , Termômetros/estatística & dados numéricosRESUMO
BACKGROUND: Researchers in observational studies of vaccine effectiveness (VE) in which they compared quadrivalent live attenuated vaccine (LAIV4) and inactivated influenza vaccine (IIV) among children and adolescents have shown inconsistent results, and the studies have been limited by small samples. METHODS: We combined data from 5 US studies from 2013-2014 through 2015-2016 to compare the VE of LAIV4 and IIV against medically attended, laboratory-confirmed influenza among patients aged 2 to 17 years by influenza season, subtype, age group, and prior vaccination status. The VE of IIV or LAIV4 was calculated as 100% × (1 - odds ratio), comparing the odds of vaccination among patients who were influenza-positive to patients who were influenza-negative from adjusted logistic regression models. Relative effectiveness was defined as the odds of influenza comparingLAIV4 and IIV recipients. RESULTS: Of 17 173 patients aged 2 to 17 years, 4579 received IIV, 1979 received LAIV4, and 10 615 were unvaccinated. Against influenza A/H1N1pdm09, VE was 67% (95% confidence interval [CI]: 62% to 72%) for IIV and 20% (95% CI: -6% to 39%) for LAIV4. Results were similar when stratified by vaccination in the previous season. LAIV4 recipients had significantly higher odds of influenza A/H1N1pdm09 compared with IIV recipients (odds ratio 2.66; 95% CI: 2.06 to 3.44). LAIV4 and IIV had similar effectiveness against influenza A/H3N2 and B. Our overall findings were consistent when stratified by influenza season and age group. CONCLUSIONS: From this pooled individual patient-level data analysis, we found reduced effectiveness of LAIV4 against influenza A/H1N1pdm09 compared with IIV, which is consistent with published results from the individual studies included.
Assuntos
Vacinas contra Influenza/uso terapêutico , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Influenza Humana/diagnóstico , Masculino , Resultado do Tratamento , Estados Unidos/epidemiologia , Vacinas Atenuadas/uso terapêutico , Vacinas de Produtos Inativados/uso terapêuticoRESUMO
Previous studies reported the presence of Helicobacter pylori in middle ear fluid and raised a possible causal role of this bacterium in otitis media with effusion (OME). We investigated 48 children with OME (age, 7 months to 12 years) seen in New Orleans, Louisiana, and found no evidence of H pylori presence in any middle ear fluid specimen by amplification of the 16S rRNA gene. One child had H pylori detected in a stool specimen, in accordance with the low prevalence in our population. While H pylori may be significant in other countries, these findings do not support a role for H pylori in OME in our pediatric population in the United States.
RESUMO
Chromobacterium violaceum is a rare, potentially serious pathogen. Most clinicians have no experience with its clinical appearance or treatment. We describe a case of a child presenting with necrotizing pneumonia caused by C. violaceum. We describe case complexities, including the need for a multidisciplinary approach to diagnosis and treatment.
Assuntos
Chromobacterium/patogenicidade , Infecções por Bactérias Gram-Negativas/imunologia , Hospedeiro Imunocomprometido , Pneumonia Necrosante/imunologia , Antibacterianos/uso terapêutico , Criança , Chromobacterium/efeitos dos fármacos , Chromobacterium/isolamento & purificação , Ciprofloxacina/uso terapêutico , Feminino , Infecções por Bactérias Gram-Negativas/diagnóstico por imagem , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Infecções por Bactérias Gram-Negativas/patologia , Humanos , Unidades de Terapia Intensiva , Meropeném/uso terapêutico , Pneumonia Necrosante/diagnóstico por imagem , Pneumonia Necrosante/tratamento farmacológico , Pneumonia Necrosante/patologia , Microbiologia do Solo , Tomografia Computadorizada por Raios XRESUMO
A vaccine could alleviate major morbidity and mortality associated with Helicobacter pylori infection. We immunized BALB/c mice with 3 doses of a protein or DNA vaccine based on H pylori urease B. Protein alone was immunogenic even after the first dose, whereas DNA did not elicit antibodies after 3 doses. DNA preceding protein (D-P-P) appeared to blunt the response to protein, whereas DNA following protein (P-D-D) shifted from a predominantly T helper 2 (Th2) profile to a balanced Th1:Th2 profile. These preliminary findings may have important implications for the development of an H pylori vaccine.
Assuntos
Proteínas de Bactérias/uso terapêutico , Vacinas Bacterianas/uso terapêutico , DNA/imunologia , Helicobacter pylori/enzimologia , Urease/imunologia , Vacinas de DNA/uso terapêutico , Animais , Proteínas de Bactérias/imunologia , Vacinas Bacterianas/imunologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Ensaio de Imunoadsorção Enzimática , Feminino , Infecções por Helicobacter/prevenção & controle , Helicobacter pylori/imunologia , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Vacinação/métodos , Vacinas de DNA/imunologiaRESUMO
BACKGROUND: Trivalent inactivated and live attenuated influenza vaccines (IIV3 and LAIV3) have been reformulated with an extra B strain (IIV4 and LAIV4). They were licensed based on immunogenicity and their effectiveness (VE) still must be empirically tested. METHODS: Children 1-17years tested for influenza during 2013-16 were included and their immunization status verified. They were considered vaccinated if received ≥1 dose of an influenza vaccine ≥10days before evaluated for a respiratory episode. Age-groups were classified as 1-4years or 5-17years. VE was estimated by comparing vaccination status of influenza-positive versus influenza-negative cases. RESULTS: 6779 children were enrolled in the three seasons. Overall, 27.2% received an influenza vaccine (87.1% IIV3 or IIV4 and 12.9% LAIV4), and 15.6% tested positive for influenza (77.9% A). IIV3 was predominantly used in 2013-14 and IIV4 in 2014-15 and 2015-16. IIV3 and IIV4 had comparable VE over the three seasons (60%, 57% and 53%) and performed similarly against influenza A and B and both age-groups. LAIV4 performed poorly for influenza A (15%, 37% and 48%) but better for influenza B (100%, 56% and 100%), especially among children 5-17years of age with VE=100% (95%CI: 55, 100). CONCLUSIONS: Influenza vaccination showed modest but consistent effectiveness over the years. The switch from IIV3 to IIV4 did not affect VE. LAIV4 did not perform as well as IIVs, yet it improved over the years and was particularly good protecting older children against influenza B. These results emphasize the regional nature of influenza and the need for local surveillance.
Assuntos
Vacinas contra Influenza/administração & dosagem , Vacinas contra Influenza/imunologia , Influenza Humana/prevenção & controle , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Vírus da Influenza A/imunologia , Vírus da Influenza B/imunologia , Masculino , Resultado do Tratamento , Vacinas Atenuadas/administração & dosagem , Vacinas Atenuadas/imunologia , Vacinas de Produtos Inativados/administração & dosagem , Vacinas de Produtos Inativados/imunologiaRESUMO
BACKGROUND: The rhesus rotavirus tetravalent vaccine (RotaShield) had an efficacy of 75%-100% in preventing severe rotavirus disease in prelicensure clinical trials. Before RotaShield's withdrawal because of reports of intussusception, there was an opportunity to evaluate the postlicensure effectiveness of the vaccine. The objective of this study was to determine the effectiveness of the RotaShield vaccine against rotavirus gastroenteritis requiring hospitalization and to evaluate factors associated with vaccine receipt. METHODS: Rotavirus cases were identified through active hospital-based rotavirus surveillance at 3 children's hospitals in Cincinnati, New Orleans and Providence. Cases were selected if they had been eligible for vaccine during the 10-month period when vaccine was available. Controls were matched to cases by date and county or state of birth. Immunization records were obtained from cases and controls to document receipt of RotaShield. Vaccine effectiveness (VE) was calculated for 1, 2, and 3 doses of vaccine with 95% confidence intervals (CI). RESULTS: For the 10-month period, 136 cases and 440 controls were enrolled. For 3 versus 0 doses of RotaShield, the VE was 100% (CI: 75%, 100%); for 2 versus 0 doses, the VE was 100% (CI: 62%, 100%), and for 1 versus 0 doses the VE was 89% (CI: 49%, 97%). RotaShield receipt was associated with white race, having more than 1 adult in the household, having insurance and having an older, more educated mother. CONCLUSIONS: This postlicensure study of RotaShield effectiveness found the vaccine to be highly effective in preventing rotavirus disease requiring hospitalization.
Assuntos
Programas de Imunização , Infecções por Rotavirus/prevenção & controle , Vacinas contra Rotavirus , Animais , Estudos de Casos e Controles , Pré-Escolar , Feminino , Gastroenterite/prevenção & controle , Gastroenterite/virologia , Hospitalização , Humanos , Lactente , Masculino , Rotavirus/imunologia , Infecções por Rotavirus/virologia , Vacinas contra Rotavirus/administração & dosagem , Resultado do TratamentoRESUMO
OBJECTIVE: The objective of this case-control study nested within a surveillance study conducted at 3 hospitals (Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Children's Hospital of New Orleans, New Orleans, LA; and Hasbro Children's Hospital, Providence, RI) was to identify risk factors for rotavirus gastroenteritis requiring hospitalization. PATIENTS: Cases were children < or =59 months of age who were admitted with acute gastroenteritis (AGE) and found to have rotavirus infection. Controls were selected from a birth certificate registry (Cincinnati and Providence) or a registry of patients from a large practice consortium in 11 locations (New Orleans). RESULTS: Three hundred forty-nine rotavirus-infected cases and 1242 control subjects were enrolled. Breast feeding was protective against hospitalization for rotavirus AGE for infants <6 months of age. (odds ratio [OR], 5.1; 95% confidence interval [CI], 1.2-13.2). Low-birth-weight (<2500 g) infants had increased risk for hospitalization even beyond the first few months of life (OR, 2.8; 95% CI, 1.6-5.0). Children in child care were more likely to be hospitalized for rotavirus AGE than those cared for at home, particularly those > or =24 months of age (OR, 3.0; 95% CI, 1.8-5.3). Other characteristics associated with rotavirus AGE hospitalization were children <24 months of age covered by Medicaid or without insurance (OR, 2.1; 95% CI, 1.4-3.2) and having another child in the house <24 months of age (OR, 1.6; 95% CI, 1.1-2.3). The data suggest that maternal age <25 years (OR, 1.4; 95% CI, 1.0-2.0) and a mother with less than a high school education (OR, 1.5; 95% CI, 1.0-2.3) may also increase risk of rotavirus hospitalization. CONCLUSION: There are socioeconomic and environmental factors and aspects of the child's medical and dietary history that identify children at risk for hospitalization with rotavirus AGE.
Assuntos
Gastroenterite/epidemiologia , Hospitalização/estatística & dados numéricos , Infecções por Rotavirus/epidemiologia , Rotavirus/isolamento & purificação , Fatores Etários , Aleitamento Materno , Estudos de Casos e Controles , Cuidado da Criança , Pré-Escolar , Educação , Feminino , Gastroenterite/virologia , Humanos , Lactente , Recém-Nascido de Baixo Peso , Recém-Nascido , Masculino , Razão de Chances , Fatores de Risco , Infecções por Rotavirus/virologia , Fatores Socioeconômicos , Estados UnidosRESUMO
Extrahepatic symptoms during chronic hepatitis C virus (HCV) infection are common and varied. Arthritis can be seen either as part of autoimmune processes (eg, associated with cryoglobulinemia) or independently. Whether the manifestation is specifically attributable to HCV infection or rather to the nonspecific result of a chronic inflammatory process is not clear. The literature available at this time is insufficient to guide the most appropriate course of treatment of HCV arthritis. Standard antirheumatic treatment can be considered, but with caution, because some of these medications occasionally may be hepatotoxic and response to therapy seems variable. Treatment decisions should be determined on a case-by-case basis.
Assuntos
Artrite/virologia , Hepatite C Crônica/complicações , Antirreumáticos/uso terapêutico , Antivirais/uso terapêutico , Artrite/tratamento farmacológico , Artrite/epidemiologia , Artrite/fisiopatologia , Feminino , Hepacivirus/efeitos dos fármacos , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/virologia , Humanos , Masculino , Resultado do TratamentoRESUMO
BACKGROUND: Pediatric Candida infections are associated with worse clinical outcomes and increased costs. Yet, it is not definitively known if particular species are associated with more severe illness. Differential risk factor exposures among the species group may also exist. We aimed to determine whether certain Candida species are more strongly associated with worse outcomes, and whether certain risk factors more strongly predispose patients to infection with certain species. METHODS: Microbiology lab records from patients seen from 2003 to 2010 at an urban children's hospital were reviewed for invasive or disseminated Candida infections. Data on measures of disease severity/outcome and risk factors were abstracted and analyzed to determine differences associated with various Candida species. RESULTS: Exactly 106 cases of infection were analyzed. Non-albicans species were associated with a significantly longer length of stay postdiagnosis (P=0.03), as well as longer treatment (P=0.02). Candida albicans was associated with a higher number of antihypotensive medications required (P=0.03) and length of mechanical ventilation postdiagnosis (P=0.05). Candida tropicalis was associated with the highest mortality (45.5%). Hypotension, which was found to be significantly associated with concurrent infection, was significantly associated with increased risk of mortality (odds ratio =5.85, P=0.005). Initial choice of antifungal therapy was not associated with differences in eventual patient mortality. Multivariate logistic regression modeling revealed a trend toward C. albicans infection in patients receiving antineoplastic chemotherapy and non-albicans infection in patients with >96 hours mechanical ventilation. CONCLUSION: Interspecies differences may exist for Candida in terms of disease severity and risk factors. Underlying morbidity and the role of concurrent infections may play a key role in poor outcomes.
RESUMO
Osteomyelitis of the clavicle is a rare entity with a broad differential diagnosis and high potential for complications if not diagnosed promptly and treated appropriately. The threshold for surgical intervention should be low to prevent osteonecrosis and bony resorption. In addition, although rare, life-threatening complications have been reported. This report describes primary osteomyelitis of the clavicle that was diagnosed in a 22-month-old girl on her third clinical evaluation after 4 days of symptoms. She presented to a children's tertiary care emergency department with fever and acute pain and swelling of her right shoulder and arm. The diagnosis was confirmed through clinical, laboratory, and imaging studies including ultrasound; these revealed subperiosteal abscess formation, which may have developed in part as the result of a delayed diagnosis from the 2 prior emergency department visits. The patient was treated initially with intravenous antibiotics and underwent therapeutic as well as diagnostic needle-guided tissue aspiration under ultrasound guidance. This ruled out malignancy but was not curative, and the subperiosteal abscess recurred within 24 hours, prompting formal operative irrigation and debridement. The patient was seen for 12-month follow-up and has had no complications or evidence of recurrence. This case emphasizes the need for a high index of suspicion to prevent diagnostic delays as well as the importance of a low threshold for surgical debridement to minimize the potential for complications that could prolong the treatment course. [Orthopedics. 2016; 39(4):e760-e763.].
Assuntos
Abscesso/diagnóstico por imagem , Clavícula/diagnóstico por imagem , Osteomielite/diagnóstico por imagem , Abscesso/tratamento farmacológico , Abscesso/cirurgia , Antibacterianos/uso terapêutico , Desbridamento , Diagnóstico Tardio , Diagnóstico Diferencial , Feminino , Humanos , Lactente , Imageamento por Ressonância Magnética , Osteomielite/tratamento farmacológico , Osteomielite/cirurgia , RadiografiaRESUMO
Löffler syndrome, a fulminant eosinophilic pneumonitis associated with the larval migratory phase of human parasites, is rarely reported in the United States. A previously healthy 8-year-old male was hospitalized with tachypnea, cough, hypoxemia, and fever of one week's duration. History revealed exposure to pigs on his family's farm in southernmost Louisiana, where the patient was responsible for cleaning the farm's pigpens. His fingernails were soiled and extremely short, with the edge of the nail bed exposed secondary to onychophagia. Laboratory evaluation demonstrated peripheral eosinophilia (39%), pulmonary eosinophilia (86%), high total IgE, diffuse reticulonodular lung opacities, and mixed obstructive and restrictive pulmonary function pattern. Systemic corticosteroids were initiated for his acute respiratory insufficiency and produced rapid clinical improvement. Serum Ascaris-specific IgE was markedly elevated and he was treated with albendazole. An extensive evaluation for other infectious and allergic etiologies was negative. A site visit to the family farm and laboratory investigation was coordinated with the Louisiana Animal Disease Diagnostic Laboratory at LSU. Ascaris suum eggs were detected in fresh pig feces and in the soil immediately surrounding the pens. Ascariasis should be considered even in the absence of travel history, especially in swine raising areas that are endemic for Ascaris in pigs, such as the southeastern United States. Onychophagia is a highly probable mechanism of zoonotic fecal-oral transmission in this case, and such habits could lead to continual reinfection. Systemic corticosteroids were effective in treating the patient's acute respiratory compromise due to Löffler syndrome.
RESUMO
OBJECTIVE: To describe practices for influenza vaccination of healthcare personnel (HCP) with emphasis on correlates of increased vaccination rates. DESIGN: Survey. PARTICIPANTS: Volunteer sample of hospitals in Louisiana. METHODS: All hospitals in Louisiana were invited to participate. A 17-item questionnaire inquired about the hospital type, patients served, characteristics of the vaccination campaign, and the resulting vaccination rate. RESULTS: Of 254 hospitals, 153 (60%) participated and were included in the 124 responses that were received. Most programs (64%) required that HCP either receive the vaccine or sign a declination form, and the rest were exclusively voluntary (36%); no program made vaccination a condition of employment. The median vaccination rate was 67%, and the vaccination rate was higher among hospitals that were accredited by the Joint Commission; provided acute care; served children, pregnant women, oncology patients, or intensive care unit patients; required a signed declination form; or imposed consequences for unvaccinated HCP (the most common of which was to require that a mask be worn on patient contact). Hospitals that provided free vaccine, made vaccine widely available, advertised the program extensively, required a declination form, and imposed consequences had the highest vaccination rates (median, 86%; range, 81%-91%). CONCLUSIONS: The rate of influenza vaccination of HCP remains low among the hospitals surveyed. Recommended practices may not be enough to reach 90% vaccination rates unless a signed declination requirement and consequences are implemented. Wearing a mask is a strong consequence. Demanding influenza vaccination as a condition of employment was not reported as a practice by the participating hospitals.
Assuntos
Vacinas contra Influenza/uso terapêutico , Recursos Humanos em Hospital/estatística & dados numéricos , Infecção Hospitalar/prevenção & controle , Pesquisas sobre Atenção à Saúde , Hospitais , Humanos , Influenza Humana/prevenção & controle , Louisiana/epidemiologia , Programas Obrigatórios/estatística & dados numéricos , Inquéritos e Questionários , Programas Voluntários/estatística & dados numéricos , Recursos HumanosAssuntos
Anticorpos Monoclonais/efeitos adversos , Fármacos Gastrointestinais/efeitos adversos , Histoplasmose/induzido quimicamente , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto , Anticorpos Monoclonais/imunologia , Doença de Crohn/tratamento farmacológico , Humanos , Infliximab , MasculinoRESUMO
OBJECTIVE: To describe the implementation of a program for the use of palivizumab in a general pediatrics office and evaluate adherence to the 2009 American Academy of Pediatrics (AAP) guidelines. METHODS: Pediatricians in a large practice were educated in the diagnosis and management of bronchiolitis, with specific attention to the AAP's palivizumab administration guidelines. During the 2009-2010 and 2010-2011 respiratory syncytial virus seasons, children were systematically identified and enrolled for palivizumab administration. Indication for administration was determined by gestational age, age at the beginning of the respiratory syncytial virus season, pertinent diagnoses, and presence of risk factors. RESULTS: In the 2009-2010 season, 161 children were enrolled to receive palivizumab, 86 of whom (53%) conformed with AAP guidelines. In contrast, in 2010-2011, a total of 85 children were enrolled to receive palivizumab, and 73 (86%) conformed with the guidelines. As a consequence, the total cost of palivizumab (US $: 511 559 vs 1 500 670) and the cost per child (US $: 6018 vs 9438) were lower in 2010-2011 than in 2009-2010. However, of the children selected within the AAP guidelines, only 29% received the appropriate number of doses, whereas 62% and 9% received fewer or excessive doses, respectively; these findings were similar for the 2 seasons. CONCLUSIONS: In a primary practice, use of palivizumab outside of the AAP guidelines was frequent and manifested as inadequate indications or inadequate number of doses. The former improved with education and standardization of care (suggesting provider problems), while the latter did not (suggesting system problems). Additional interventions are required.